

<b>Tumor characteristics</b>	<b>Synchronous prophylactic and therapeutic mastectomies N=24 (100%)</b>	<b>Breast cancer in the past (post mastectomy or post conservative) N=17 (100%)</b>
<b>Histology</b>		
- Ductal <i>in situ</i>	6 (25)	1 (6)
- Invasive ( <i>not otherwise specified</i> )	18 (75)	16 (94)
<b>Clinical Stage</b>		
- 0	5 (20)	1 (6)
- I	10 (42)	3 (18)
- II	7 (29)	1 (6)
- III	0 (0)	5 (29)
- IV	0 (0)	0 (0)
- Unknown	2 (14)	7 (41)
<b>Other treatments</b>	<i>(only neoadjuvant)</i>	<i>(neo – or adjuvant)</i>
- Chemotherapy	4 (17)	10 (59)
- Radiotherapy	0	10 (59)
- Hormonotherapy	0	8 (47)
- No data	-	5 (29)
<b>Time interval between surgeries</b>	-	90 months $\pm$ 56 (10–228)

**Supplementary Table 1. Tumor characteristics and oncologic treatments received - other than surgical – in women with breast cancer (either synchronous to prophylactic mastectomy or prior to it)**